A federal lawsuit filed in June 2026 is shining a harsh spotlight on one of the most dangerous medical device failures of the decade: contaminated Olympus duodenoscopes that allegedly cannot be adequately cleaned or disinfected, even when hospital staff follow the manufacturer’s own reprocessing instructions. The plaintiff in this case underwent an Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure in June 2023, contracted Vancomycin-Resistant Enterococcus (VRE), and ultimately died from septic shock and multi-organ failure. The Olympus duodenoscope infection lawsuit now making its way through federal court is not an isolated incident — it is the latest chapter in a years-long regulatory and litigation crisis that has claimed lives, prompted multiple FDA recalls, and left thousands of ERCP patients wondering whether the scope used in their procedure put them at risk.
What Is the Olympus Duodenoscope and Why Is It Dangerous?
Duodenoscopes are specialized, flexible endoscopes threaded through the mouth to reach the small intestine. They are essential for ERCP procedures, which diagnose and treat conditions affecting the bile ducts, pancreas, and gallbladder. The Olympus TJF-Q190V is among the most widely used models in U.S. hospitals. The device features a complex, elevator mechanism at its tip — a small moveable part that guides surgical tools during the procedure. This elevator, and the multiple narrow internal channels surrounding it, creates microscopic crevices that standard cleaning brushes and chemical disinfectants cannot reliably penetrate.
The scale of the contamination problem has been documented in striking detail by regulators and litigants alike. An FDA-required postmarket study cited in 2026 litigation found that only 34.8% of sampled reprocessed endoscopes were free of contamination — meaning more than six in ten scopes tested positive even after cleaning. Between 2013 and 2024, contaminated Olympus duodenoscopes infected hundreds of patients, with at least 35 deaths reported. According to the CDC’s guidance on healthcare-associated outbreaks linked to duodenoscopes, these devices have been associated with clusters of multi-drug-resistant organism infections across U.S. hospitals. When bacteria like VRE survive inside the scope’s channels, the next patient who undergoes an ERCP procedure is directly inoculated with drug-resistant pathogens through their bile duct — one of the fastest routes to bloodstream infection and sepsis.
The June 2026 Federal Lawsuit: Key Allegations Against Olympus
The complaint filed in June 2026 centers on two primary legal theories: strict liability design defect and failure to warn. Under the strict liability design defect claim, plaintiffs argue the Olympus TJF-Q190V was unreasonably dangerous because its multi-channel, elevator-assisted architecture made thorough reprocessing impossible — not due to user error, but due to the device’s fundamental engineering. The failure-to-warn claim alleges that Olympus knew, or should have known, that its reprocessing instructions were inadequate to eliminate bacterial contamination at the levels required for patient safety, yet failed to communicate that risk clearly to hospitals, physicians, and patients.
The postmarket contamination data strengthens both theories considerably. When only 34.8% of reprocessed scopes pass a basic contamination screen, plaintiffs argue, no reasonable interpretation of the evidence supports the conclusion that the cleaning failure rests with hospital staff. Olympus’s own October 2025 field safety notice acknowledged two deaths and five serious injuries from infection since 2024 linked to duodenoscopes — an admission that attorneys for plaintiffs have cited as powerful evidence that the company was aware of ongoing patient harm well before the June 2026 lawsuit was filed.
These are precisely the liability theories that courts have found most persuasive in medical device mass torts. As Cornell Law School’s Legal Information Institute explains, strict products liability does not require proof of negligence — a plaintiff need only show the product was defective and the defect caused injury. In the context of an Olympus duodenoscope infection lawsuit, that means demonstrating that the scope’s design made it incapable of safe reprocessing and that a patient suffered a serious infection as a result.
FDA Regulatory History: Recalls That Build the Case
The regulatory record surrounding Olympus duodenoscopes is extensive and damaging. FDA warnings, safety communications, and formal recalls dating back years have repeatedly flagged the same core problem: the elevator mechanism and internal channel architecture of these devices cannot be reliably decontaminated using standard reprocessing protocols. Each regulatory action adds another layer to the evidentiary foundation plaintiffs’ attorneys are assembling in 2026 litigation.
The most recent and significant regulatory action came in March 2026, when both the FDA and Health Canada issued recalls covering Olympus MAJ-1443 and MAJ-1444 valves used with the OER-Pro reprocessor. Regulators determined that these valves were incompatible with the reprocessor in ways that compromised the disinfection process — meaning hospitals using this equipment combination may have believed their scopes were being adequately cleaned when they were not. For plaintiffs who underwent ERCP procedures at facilities using the OER-Pro system with these valves, the March 2026 recall provides direct, contemporaneous evidence of a documented disinfection failure tied to Olympus equipment.
Attorneys litigating these cases in 2026 are using this layered regulatory history — spanning more than a decade of FDA communications, culminating in the March 2026 recall — to argue that Olympus had ample notice of these dangers and repeatedly failed to act with the urgency that patient safety demanded.
Damages Framework: How Much Is an Olympus Duodenoscope Infection Lawsuit Worth?
Compensation in an Olympus duodenoscope infection lawsuit depends on the severity of the harm suffered, the strength of the causal link between the contaminated scope and the infection, and the specific economic and non-economic losses the plaintiff can document. While no global settlement or verdicts have been reached in the current wave of Olympus scope litigation as of 2026, the damages framework applied in these cases draws on well-established principles from medical device and pharmaceutical mass tort litigation.
Economic damages typically include past and future medical expenses, lost wages and earning capacity, and the cost of ongoing care for patients who survive serious infections but suffer lasting health consequences. Non-economic damages — which often represent the largest component of recovery in catastrophic injury and wrongful death cases — encompass physical pain and suffering, emotional distress, loss of enjoyment of life, and, in wrongful death claims, the loss of companionship and financial support sustained by surviving family members.
In cases involving documented VRE or other multi-drug-resistant infections following ERCP, where patients required extended ICU stays, multiple surgeries, or where death resulted, total damages demands have historically reached into the millions of dollars per plaintiff. Punitive damages may also be available in jurisdictions that permit them where a manufacturer’s conduct is found to reflect conscious disregard for patient safety — and the combination of Olympus’s October 2025 field safety notice acknowledging ongoing deaths and the FDA’s March 2026 recall may support such claims in appropriate cases.
MDL Formation, Bellwether Trials, and Settlement Trajectory
As of 2026, no global settlement has been reached in the second wave of Olympus duodenoscope lawsuits, and no bellwether verdicts have been returned. The litigation remains in active development, with plaintiffs’ attorneys continuing to file individual federal complaints and courts evaluating whether consolidation into a formal multidistrict litigation (MDL) is appropriate given the volume and geographic spread of filed cases.
MDL consolidation, when it occurs in mass tort litigation, allows a single federal judge to manage pretrial proceedings — including discovery, expert witness challenges, and dispositive motions — on behalf of all transferred cases. This process typically produces bellwether trials: a small number of representative cases selected to go to trial first, with outcomes that inform settlement negotiations for the broader inventory of claims. In prior Olympus-related litigation, the MDL and bellwether process played a central role in how cases were ultimately resolved.
The absence of a global settlement in 2026 does not mean recovery is unavailable to current plaintiffs. Individual cases can proceed to trial or reach negotiated resolution independently, and the evidentiary record — including the postmarket contamination data, the October 2025 field safety notice, and the March 2026 recall — continues to strengthen as litigation progresses. Plaintiffs’ attorneys are monitoring consolidation developments closely and advising clients to preserve all relevant medical records and documentation while the litigation landscape evolves.
Who May Be Eligible to File an Olympus Duodenoscope Infection Lawsuit?
Potential plaintiffs in an Olympus duodenoscope infection lawsuit in 2026 generally share a common fact pattern: they underwent an ERCP procedure using an Olympus duodenoscope, developed a serious infection in the days or weeks following the procedure — particularly infections caused by multi-drug-resistant organisms such as VRE, CRE, or MRSA — and suffered significant harm as a result. Family members of patients who died from post-ERCP infections may also be eligible to bring wrongful death claims.
Eligibility is not limited to patients who had procedures at facilities named in prior regulatory actions. Because the contamination problem is rooted in the device’s design rather than any single hospital’s cleaning practices — a conclusion powerfully supported by the finding that only 34.8% of reprocessed scopes were contamination-free even when cleaned per manufacturer instructions — patients treated at a wide range of U.S. hospitals may have viable claims. Similarly, patients treated at facilities that used the OER-Pro reprocessor with the recalled MAJ-1443 or MAJ-1444 valves should discuss their situation with an attorney regardless of whether their facility received direct notice of the March 2026 recall before their procedure.
Statutes of limitations vary by state, and in wrongful death cases the clock typically begins running from the date of death rather than the date of the procedure. Because these deadlines can be as short as two years in some jurisdictions, anyone who believes they or a family member may have been harmed by a contaminated Olympus duodenoscope should consult with a personal injury attorney as promptly as possible to preserve their legal rights.
Frequently Asked Questions About the Olympus Duodenoscope Infection Lawsuit
What is the Olympus duodenoscope infection lawsuit about?
The Olympus duodenoscope infection lawsuit involves claims that Olympus designed and sold duodenoscopes — flexible medical devices used in ERCP procedures — that cannot be adequately cleaned or disinfected even when hospitals follow the manufacturer’s own reprocessing instructions. Plaintiffs allege that this design defect allowed dangerous bacteria, including multi-drug-resistant organisms, to survive inside the scope and infect subsequent patients. Between 2013 and 2024, contaminated Olympus duodenoscopes were linked to hundreds of patient infections and at least 35 deaths. Olympus’s own October 2025 field safety notice acknowledged two additional deaths and five serious injuries from scope-related infections since 2024. The 2026 federal lawsuit described in this article is part of a continuing wave of litigation holding Olympus accountable for these harms.
What FDA recalls support the Olympus duodenoscope infection claims?
The FDA regulatory record includes years of safety communications, warnings, and formal recalls targeting Olympus duodenoscopes. The most recent action occurred in March 2026, when the FDA and Health Canada jointly recalled Olympus MAJ-1443 and MAJ-1444 valves used with the OER-Pro reprocessor after determining that these components were incompatible with the reprocessing system in ways that compromised disinfection. Prior recalls and safety communications addressed the elevator mechanism design, inadequate reprocessing instructions, and the persistent failure of these devices to meet contamination-free standards across real-world hospital settings. An FDA-required postmarket study found that only 34.8% of sampled reprocessed endoscopes were free of contamination — data that plaintiffs’ attorneys are citing prominently in 2026 litigation.
How much compensation can victims recover in an Olympus duodenoscope lawsuit?
Compensation in an Olympus duodenoscope lawsuit can include economic damages such as medical expenses, lost income, and future care costs, as well as non-economic damages for pain and suffering, emotional distress, and loss of enjoyment of life. Wrongful death cases may also include damages for loss of companionship and financial support. In catastrophic cases involving extended ICU care, permanent disability, or death, total damages demands have historically reached into the millions of dollars. Punitive damages may be available in some jurisdictions based on evidence that Olympus was aware of ongoing patient harm — including the deaths and injuries acknowledged in its October 2025 field safety notice — and failed to act with adequate urgency. No global settlement figures have been established in the current 2026 litigation wave.
Will Olympus duodenoscope cases be consolidated into an MDL?
As of 2026, the second wave of Olympus duodenoscope lawsuits has not been consolidated into a formal MDL, and no bellwether trials or global settlements have been reached. Courts and plaintiffs’ attorneys are actively monitoring whether the volume of filed cases warrants consolidation. If an MDL is formed, it would centralize pretrial proceedings before a single federal judge and likely produce bellwether trials whose outcomes would shape settlement negotiations across the broader case inventory. Individual cases can continue to be filed and may proceed to resolution independently in the interim.
Who is eligible to file an Olympus duodenoscope infection lawsuit in 2026?
Patients who underwent an ERCP procedure using an Olympus duodenoscope and subsequently developed a serious infection — particularly one caused by a multi-drug-resistant organism such as VRE, CRE, or MRSA — may be eligible to file a lawsuit in 2026. Family members of patients who died from post-ERCP infections may have wrongful death claims. Eligibility is not confined to patients treated at previously identified outbreak facilities, given that the contamination problem is rooted in the device’s design. Patients treated at facilities using the OER-Pro reprocessor with the recalled MAJ-1443 or MAJ-1444 valves should also seek legal consultation. Because statutes of limitations vary by state and can be as short as two years, prompt consultation with a personal injury attorney is strongly advised to protect your legal rights.
James Mitchell is a personal injury legal researcher with over a decade of experience analyzing settlement data and compensation trends across the United States. He has studied thousands of personal injury cases to help injury victims understand their legal rights and the potential value of their claims. James is not an attorney and the information he provides is for
educational purposes only.